Abstract | BACKGROUND: METHODS: Clinical studies evaluating the impact of gemcitabine based regimens on response and safety for patients with osteosarcoma were identified by using a predefined search strategy. Pooled response rates (RRs) of treatment were calculated. RESULTS: In gemcitabine based regimens, 4 clinical studies which included 66 patients with recurrent or refractory osteosarcoma were considered eligible for inclusion. Systemic analysis suggested that, in all patients, pooled RR was 12.1% (8/66) in gemcitabine based regimens. Major adverse effects were hematologic toxicity, including grade 3 or 4 anemia, leucopenia and thrombocytopenia in gemcitabine based treatment. No treatment related death occurred in gemcitabine based treatment. CONCLUSION: This systemic analysis suggests that gemcitabine based regimens are associated with mild activity with good tolerability in treating patients with recurrent or refractory osteosarcoma.
|
Authors | Mei-Yang Wei, Yan-Feng Zhuang, Wan-Ming Wang |
Journal | Asian Pacific journal of cancer prevention : APJCP
(Asian Pac J Cancer Prev)
Vol. 15
Issue 17
Pg. 7159-62
( 2014)
ISSN: 2476-762X [Electronic] Thailand |
PMID | 25227807
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Deoxycytidine
- Gemcitabine
|
Topics |
- Antimetabolites, Antineoplastic
(therapeutic use)
- Bone Neoplasms
(drug therapy)
- Deoxycytidine
(analogs & derivatives, therapeutic use)
- Humans
- Osteosarcoma
(drug therapy)
- Treatment Outcome
- Gemcitabine
|